Document Detail


Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review.
MedLine Citation:
PMID:  23402443     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Dabigatran etexilate is a newly approved agent for prophylaxis of stroke in atrial fibrillation. Through narrative review, the authors assess evidence of the efficacy of dabigatran in stroke prevention, focusing on the multicenter, randomized trial RE-LY. The authors complement this with a review of the clinical efficacy of standard treatments (antiplatelet and warfarin). Finally, the authors present a systematic review of published studies describing the economics of dabigatran. Our systematic search gave six economic reviews from a variety of healthcare systems (the USA, Canada and the UK) and utilizing different economic models. Analyses suggest economic benefit of high- or sequential-dose dabigatran, particularly when stroke risk is high; intracerebral hemorrhage risk is high or warfarin control is poor. However, questions remain around dabigatran tolerability, compliance and possible unexpected adverse events.
Authors:
Sarah Marshall; Patricia Fearon; Jesse Dawson; Terence J Quinn
Related Documents :
11951443 - Craniofacial trauma in children.
9401893 - Epidural haematoma and stroller-associated injury.
8780743 - Is t(6;14) a non-random translocation in childhood acute mixed lineage leukemia?
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of pharmacoeconomics & outcomes research     Volume:  13     ISSN:  1744-8379     ISO Abbreviation:  Expert Rev Pharmacoecon Outcomes Res     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-02-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101132257     Medline TA:  Expert Rev Pharmacoecon Outcomes Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  29-42     Citation Subset:  IM    
Affiliation:
Institute of Cardiovascular & Medical Sciences, University of Glasgow, Walton Building, Glasgow Royal Infirmary, Glasgow G4 0SF, Scotland, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.
Next Document:  Moving the boundaries of international collaboration on clinical trials and QoL: experiences in onco...